)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Dyadic International
Dyadic International (DYAI) investor relations material
Dyadic International Lytham Partners Fall 2026 Investor Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Lytham Partners Fall 2026 Investor Conference summary29 Sep, 2026
Market positioning and technology
Entering commercial stage with multiple products across life sciences, food nutrition, and bioindustrial segments utilizing proprietary gene expression technology.
Industrially proven platforms (C1 for complex proteins, Dapibus for high-yield, low-cost production) enable scalable, sustainable, non-animal protein solutions.
Focus on life sciences for near-term revenue, with products like DNase I, albumin, transferrin, and growth factors now commercially available.
Global distribution network established, including partnerships with Integrated BioTherapeutics and Proliant Health & Biologicals.
Multiple revenue models now in place: direct sales, licensing, and profit-sharing partnerships.
Commercial execution and product launches
Products are now available through both direct and partner channels, with recurring revenues expected as adoption grows.
Recent launches include recombinant human albumin (AlbuFree DX) and bovine chymosin, targeting cell and gene therapy, diagnostics, and food markets.
Life sciences segment prioritized due to rapid growth in cell culture media and molecular biology reagents.
Regulatory and safety advantages highlighted for recombinant proteins over animal- or plant-derived sources.
Pilot sales and product sampling underway, with expectations for increased commercial traction and reorders.
Strategic partnerships and growth opportunities
Partnerships with organizations like IBT, Proliant, Inzymes, and BRIG BIO expand market reach and product offerings.
Non-dilutive collaborations with Gates Foundation and CEPI validate technology for biopharma applications.
Potential for strategic exits, collaborations, or acquisitions as product portfolio matures.
High-value enzyme opportunities (e.g., hyaluronidase) demonstrate platform's versatility and potential for new markets.
Focus remains on expanding commercial traction, distribution, and product diversification into 2027 and beyond.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Dyadic International
- Commercial execution underway with growing product sales and key partnerships driving near-term growth.DYAI
IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 - Biotech firm registers 3.6M shares for resale via warrants, proceeds fund growth and R&D.DYAIRegistration filing
- Commercial-stage protein platform drives growth with new products, partners, and recurring revenues.DYAIQ3 Investor Summit Group Virtual Conference 2026
- Scalable, animal-free protein platforms deliver rapid, high-yield solutions for global biologics markets.DYAICorporate presentation
- Flat Q2 revenue, higher costs, and cash burn widened losses and increased going concern risk.DYAIQ2 2026
- Shifted to commercial focus with new product launches, wider net loss, and strong liquidity.DYAIQ3 2025
- Q2 2025 revenue surged and net loss narrowed as commercial focus and new funding accelerated growth.DYAIQ2 2025
- Q3 2024 revenue rose 393% to $1.96M, net loss narrowed, and cash reached $10M.DYAIQ3 2024
- Revenue up 18% on grants; product launches and strong liquidity expected in 2025.DYAIQ1 2025
Next Dyadic International earnings date
Q3 202611 Nov, 2026
Dyadic International
Next Dyadic International earnings date
Q3 202611 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Dyadic International Inc. is a biotechnology company specializing in the development and commercialization of technologies for gene expression and protein production. The company’s primary platform, the C1 gene expression system, is used to produce enzymes and proteins for various industries, including biopharmaceuticals, vaccines, and industrial applications. Dyadic focuses on leveraging its proprietary technology to accelerate the development of biologics and other biotechnological products, aiming to improve production efficiency and scalability. The company is headquartered in Jupiter, Florida, and its shares are listed on the NASDAQ.